Zobrazeno 1 - 10
of 58
pro vyhledávání: '"O. Nicoletto"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Elena Biagioli, Eliana Rulli, Nicoletta Colombo, Roldano Fossati, F. Tettamanzi, Federica Tomao, A. A. Lissoni, M.F. Alvisi, Germana Tognon, Alessandra Bologna, F. Galli, O. Nicoletto, P. Benedetti Panici, Valter Torri
Publikováno v:
Annals of Oncology. 29:viii357
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd67b48ee07e6ec05c10fc4c143727ff
https://doi.org/10.1093/annonc/mdy285.209
https://doi.org/10.1093/annonc/mdy285.209
Publikováno v:
European journal of gynaecological oncology. 31(6)
About 10% of all ovarian cancers are due to BRCA 1 and/or BRCA 2 mutations. Some studies have shown that patients belonging to this group have a better survival compared to sporadic groups but data are still inconclusive. The aim of this study was to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f32e65fa6d1a4aae728df73d0244e2ac
https://pubmed.ncbi.nlm.nih.gov/21319511
https://pubmed.ncbi.nlm.nih.gov/21319511
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 16(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2e031960ac91c2ffb34210908e0e356c
https://pubmed.ncbi.nlm.nih.gov/19692431
https://pubmed.ncbi.nlm.nih.gov/19692431
Autor:
L. Del Mastro, N. Olmeo, O. Nicoletto, Claudia Bighin, S. Monfardini, Fabio Puglisi, A. Lambiase, Federico Cappuzzo, M. Venturini, Antonio Durando
The primary objective of study is to evaluate cardiac safety of trastuzumab in combination with epirubicin and docetaxel. HER2-overexpressing metastatic breast cancer patients were enrolled in a two-stage, multicenter phase II trial with weekly trast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fbc317b3af5bd5e6c812d1b64423b0a
https://hdl.handle.net/11567/890263
https://hdl.handle.net/11567/890263
Autor:
Emma D'Andrea, Gianni Sordi, V Lazzarotto, A. De Nicolo, M. Montagna, Simona Agata, G De Salvo, Luigi Chieco-Bianchi, Giuseppe Luigi Banna, O Nicoletto, Chiara Menin
Publikováno v:
Cancer letters. 168(1)
The human androgen receptor (AR) gene contains a highly polymorphic CAG repeat in exon 1 that is inversely correlated with AR transcriptional activity in vitro. Several studies have shown that fewer CAG repeats are associated with an increased risk a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ddf55f11bc731b4bbb26036f70d79d4
https://pubmed.ncbi.nlm.nih.gov/11368874
https://pubmed.ncbi.nlm.nih.gov/11368874
Publikováno v:
Journal of chemotherapy (Florence, Italy). 11(3)
Currently the surgical treatment for peritoneal carcinomatosis of epithelial ovarian cancer is radically modifying. In many surgical and oncological centers the experimentation with new and effective antineoplastic drugs has obtained good results wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d1f4ff75fd9151bd40cdd85bb2aa670
https://pubmed.ncbi.nlm.nih.gov/10435694
https://pubmed.ncbi.nlm.nih.gov/10435694
Autor:
Franco M. Muggia, M. Alvear, Elsa Reich, Tara Berman, W. C. Lai, M. O. Nicoletto, T. Safra, Izhak Haviv, L. Borgato
Publikováno v:
Annals of Oncology. 24:viii63-viii68
Background Epithelial ovarian cancer (EOC) patients with BRCA mutations have better prognosis than nonhereditary cases matched for histology and stage and age at diagnosis, especially Ashkenazi Jews (AJ). Materials and methods We retrospectively revi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e4a9e9a50925437810945dc257cb31d
https://doi.org/10.1093/annonc/mdt315
https://doi.org/10.1093/annonc/mdt315
Publikováno v:
Il Giornale di chirurgia. 14(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::70dd6b1ee2750fc2fe64dd57226f20f3
https://pubmed.ncbi.nlm.nih.gov/8489897
https://pubmed.ncbi.nlm.nih.gov/8489897
Autor:
M. O. Nicoletto, M. E. Donach, L. Borgato, F. Angelini, G. Artioli, P. Azzoni, A. Perin, C. Barile, R. Bertorelle, A. Cecchetto, G. Cartei
Publikováno v:
Journal of Clinical Oncology. 24:15054-15054
15054 Background: The efficacy of PLD+Ox in pre-treated advanced EOC in third and fourth line suggests that the elevated survival in these patients might activate the p53 pathway. Methods: Inclusion criteria: Performance Status≤2, relapse or progre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e2f765d4bfa33fb2527dc1b96bd074b
https://doi.org/10.1200/jco.2006.24.18_suppl.15054
https://doi.org/10.1200/jco.2006.24.18_suppl.15054